Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Triplet Therapeutics was a biotechnology company founded in 2018, dedicated to developing transformative treatments for repeat expansion disorders (REDs), with an initial focus on Huntington's disease. The company aimed to address the underlying genetic cause of these debilitating conditions by developing antisense oligonucleotides (ASOs). Despite raising significant funding, including a $59 million Series A round, and advancing its lead candidate, TTX-3360, into Phase Ib/IIa clinical trials, Triplet Therapeutics ceased operations in late 2022 after the program did not meet its primary objectives.
Formerly served as the primary site for research and development, clinical operations, and corporate functions.
Located in the Kendall Square biotech hub, likely utilizing modern lab and office spaces typical for research-intensive companies in a state-of-the-art life sciences building.
Historically fostered a science-driven, innovative, and collaborative environment focused on addressing urgent patient needs in neurodegenerative diseases. The team was dedicated to pioneering approaches for genetically defined disorders.
Its Cambridge location provided strategic access to a rich ecosystem of top-tier talent, world-class research institutions, and potential collaborators within the life sciences sector.
As a US-based biotechnology company, Triplet Therapeutics's core operations, including research, development, and corporate functions, were primarily centered in the United States. While its research into repeat expansion disorders had global implications for patient populations worldwide, and clinical trials may have involved international sites, its physical operational presence was concentrated domestically in Cambridge, MA.
225 Binney Street
Cambridge
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Triplet Therapeutics' leadership includes:
Triplet Therapeutics has been backed by several prominent investors over the years, including:
Triplet Therapeutics ceased operations in late 2022. Consequently, there have been no executive new hires or exits in the last 12 months (from early 2023 to early 2024). All executive roles concluded with the company's wind-down procedures.
Discover the tools Triplet Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While Triplet Therapeutics is no longer operational, biotechnology companies of its nature commonly use email formats such as [first_initial][last]@[companydomain].com or [first].[last]@[companydomain].com. These are speculative based on common industry practices.
[first_initial][last]@triplettherapeutics.com (e.g., jdoe@triplettherapeutics.com) or [first].[last]@triplettherapeutics.com (e.g., jane.doe@triplettherapeutics.com)
Format
asmith@triplettherapeutics.com (example of a plausible historical format)
Example
0%
Success rate
Endpoints News • November 30, 2022
Triplet Therapeutics announced it was ceasing operations after its lead candidate, TTX-3360, for Huntington's disease did not meet its objectives in a Phase Ib/IIa clinical trial. The company had been developing therapies for repeat expansion disorders....more
Fierce Biotech (reporting on PR Newswire release) • December 10, 2019
Triplet Therapeutics officially launched with a combined $59 million in Seed and Series A financing. The round was co-led by MPM Capital and Atlas Venture, with significant participation from Pfizer Ventures, Lightstone Ventures, Omega Funds, Gurnet Point Capital, and Alexandria Venture Investments. The company aimed to address the underlying cause of repeat expansion disorders, with an initial focus on Huntington's disease....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Triplet Therapeutics, are just a search away.